Daily 500 mg valacyclovir is effective for prevention of varicella zoster virus reactivation in patients with multiple myeloma treated with bortezomib

Anticancer Research

Volumn 32, Issue 12, 2012, Pages 5437-5440

  Fukushima, Toshihiro ^a   Sato, Tomomi ^a   Nakamura, Takuji ^a   Iwao, Haruka ^a   Nakajima, Akio ^a   Miki, Miyuki ^a   Sakai, Tomoyuki ^a   Kawanami, Takafumi ^a   Sawaki, Toshioki ^a   Fujita, Yoshimasa ^a   Tanaka, Masao ^a   Masaki, Yasufumi ^a   Okazaki, Toshiro ^a   Nakajima, Hideo ^a   Motoo, Yoshiharu ^a   Umehara, Hisanori ^a  

^a KANAZAWA MEDICAL UNIVERSITY   (Japan)

Author keywords

Acyclovir; Bortezomib; Multiple myeloma; Valacyclovir; Varicella zoster virus

Indexed keywords

BORTEZOMIB; CORTICOSTEROID; VALACICLOVIR;

ADULT; AGED; ARTICLE; DRUG EFFICACY; DRUG SAFETY; FEMALE; HERPES ZOSTER; HUMAN; MALE; MEDICAL RECORD REVIEW; MULTIPLE MYELOMA; PRIORITY JOURNAL; RETROSPECTIVE STUDY; SIDE EFFECT; TREATMENT DURATION; UNSPECIFIED SIDE EFFECT; VARICELLA ZOSTER VIRUS; VIRUS REACTIVATION;

ACYCLOVIR; AGED; AGED, 80 AND OVER; ANTINEOPLASTIC AGENTS; ANTIVIRAL AGENTS; BORONIC ACIDS; FEMALE; HERPES ZOSTER; HERPESVIRUS 3, HUMAN; HUMANS; MALE; MIDDLE AGED; MULTIPLE MYELOMA; PYRAZINES; RETROSPECTIVE STUDIES; VALINE; VIRUS ACTIVATION;

EID: 84872564552     PISSN: 02507005     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (27)

1. The International Myeloma Working Group: Criteria for the classification of monoclonal gammopathies, multiple myeloma and related disorders: A report of the International Myeloma Working Group. Br J Haematol 121: 749-757, 2003.
2. Kyle RA and Rajkumar SV: Multiple myeloma. Blood 111: 2962-2972, 2008.
3. Caers J, Vande broek I, De Raeve H, Michaux L, Trullemans F, Schots R, Van Camp B and Vanderkerken K: Multiple myeloma-an update on diagnosis and treatment. Eur J Haematol 81: 329-343, 2008.
4. Hideshima T, Mitsiades C, Akiyama M, Hayashi T, Chauhan D, Richardson P, Schlossman R, Podar K, Munshi NC, Mitsiades N and Anderson KC: Molecular mechanisms mediating antimyeloma activity of proteasome inhibitor PS-341. Blood 101: 1530-1534, 2003.
5. Hideshima T, Mitsiades C, Tonon G, Richardson PG and Anderson KC: Understanding multiple myeloma pathogenesis in the bone marrow to identify new therapeutic targets. Nat Rev Cancer 7: 585-598, 2007.
6. Richardson PG, Barlogie B, Berenson J, Singhal S, Jagannath S, Irwin D, Rajkumar SV, Srkalovic G, Alsina M, Alexanian R, Siegel D, Orlowski RZ, Kuter D, Limentani SA, Lee S, Hideshima T, Esseltine DL, Kauffman M, Adams J, Schenkein DP and Anderson KC: A phase 2 study of bortezomib in relapsed, refractory myeloma. N Engl J Med 348: 2609-2617, 2003.
7. Richardson PG, Sonneveld P, Schuster MW, Irwin D, Stadtmauer EA, Facon T, Harousseau JL, Ben-Yehuda D, Lonial S, Goldschmidt H, Reece D, San-Miguel JF, Bladé J, Boccadoro M, Cavenagh J, Dalton WS, Boral AL, Esseltine DL, Porter JB, Schenkein D and Anderson KC; Assessment of Proteasome Inhibition for Extending Remissions (APEX) Investigators: Bortezomib or high-dose dexamethasone for relapsed multiple myeloma. N Engl J Med 352: 2487-2498, 2005.
8. San Miguel JF, Schlag R, Khuageva NK, Dimopoulos MA, Shpilberg O, Kropff M, Spicka I, Petrucci MT, Palumbo A, Samoilova OS, Dmoszynska A, Abdulkadyrov KM, Schots R, Jiang B, Mateos MV, Anderson KC, Esseltine DL, Liu K, Cakana A, van de Velde H and Richardson PG; VISTA Trial Investigators: Bortezomib plus melphalan and prednisone for initial treatment of multiple myeloma. N Engl J Med 359: 906-917, 2008.
9. Harousseau JL, Attal M, Avet-Loiseau H, Marit G, Caillot D, Mohty M, Lenain P, Hulin C, Facon T, Casassus P, Michallet M, Maisonneuve H, Benboubker L, Maloisel F, Petillon MO, Webb I, Mathiot C and Moreau P: Bortezomib plus dexamethasone is superior to vincristine plus doxorubicin plus dexamethasone as induction treatment prior to autologous stem-cell transplantation in newly diagnosed multiple myeloma: Results of the IFM 2005-01 phase III trial. J Clin Oncol 28: 4621-4629, 2010.
10. Fukushima T, Nakamura T, Iwao H, Nakajima A, Miki M, Sato T, Sakai T, Sawaki T, Fujita Y, Tanaka M, Masaki Y, Nakajima H, Motoo Y and Umehara H: Efficacy and safety of bortezomib plus dexamethasone therapy for refractory or relapsed multiple myeloma: Once-weekly administration of bortezomib may reduce the incidence of gastrointestinal adverse events. Anticancer Res 31: 2297-2302, 2011.
11. Nucci M and Anaissie E: Infections in patients with multiple myeloma in the era of high-dose therapy and novel agents. Clin Infect Dis 49: 1211-1225, 2009.
12. Chanan-Khan A, Sonneveld P, Schuster MW, Stadtmauer EA, Facon T, Harousseau JL, Ben-Yehuda D, Lonial S, Goldschmidt H, Reece D, Neuwirth R, Anderson KC and Richardson PG: Analysis of herpes zoster events among bortezomib-treated patients in the phase III APEX study. J Clin Oncol 26: 4784-4790, 2008.
13. Vickrey E, Allen S, Mehta J and Singhal S: Acyclovir to prevent reactivation of varicella zoster virus (herpes zoster) in multiple myeloma patients receiving bortezomib therapy. Cancer 115: 229-232, 2009.
14. Pour L, Adam Z, Buresova L, Krejci M, Krivanova A, Sandecka V, Zahradova L, Buchler T, Vorlicek J and Hajek R: Varicellazoster virus prophylaxis with low-dose acyclovir in patients with multiple myeloma treated with bortezomib. Clin Lymphoma Myeloma 9: 151-153, 2009.
15. Kim SJ, Kim K, Do YR, Bae SH, Yang DH and Lee JJ: Low-dose acyclovir is effective for prevention of herpes zoster in myeloma patients treated with bortezomib: A report from the Korean Multiple Myeloma Working Party (KMMWP) Retrospective Study. Jpn J Clin Oncol 41: 353-357, 2011.
16. Aoki T, Nishiyama T, Imahashi N and Kitamura K: Efficacy of continuous, daily, oral, ultra-low-dose 200 mg acyclovir to prevent herpes zoster events among bortezomib-treated patients: A report from retrospective study. Jpn J Clin Oncol 41: 876-881, 2011.
17. Swaika A, Paulus A, Miller KC, Sher T, Almyroudis NG, Ball D, Wood M, Masood A, Lee K and Chanan-Khan AA: Acyclovir prophylaxis against varicella zoster virus reactivation in multiple myeloma patients treated with bortezomib-based therapies: A retrospective analysis of 100 patients. J Support Oncol 10: 155-159, 2012.
18. National Comprehensive Cancer Network (NCCN). NCCN Clinical Practice Guilelines in Oncology, Prevention and Treatment of Cancer-Related Infection (version 1.2012). 2011. http://www.nccn.org/professionals/physician-gls/pdf/ infections.pdf
19. Greipp PR, San Miguel J, Durie BGM, Crowley JJ, Barlogie B, Bladé J, Boccadoro M, Child JA, Avet-Loiseau H, Kyle RA, Lahuerta JJ, Ludwig H, Morgan G, Powles R, Shimizu K, Shustik C, Sonneveld P, Tosi P, Turesson I and Westin J: International Staging System for multiple myeloma. J Clin Oncol 23: 3412-3420, 2005.
20. National Cancer Institute: National Cancer Institute Cancer Therapy Evaluation Program Common Terminology Criteria for Adverse Events, Version 3.0. 9 August 2006. http://ctep.cancer.gov/protocolDevelopment/electronic- applications/ctc.htm#ctc-30
21. Kim SJ, Kim K, Kim BS, Lee HJ, Kim H, Lee NR, Nam SH, Kwon JH, Kim HJ, Sohn SK, Won JH, Lee JH, Suh C, Yoon SS, Kim HJ, Kim I, Do YR, Lee WS, Joo YD and Shin HJ; Korean Multiple Myeloma Working Party: Bortezomib and the increased incidence of herpes zoster in patients with multiple myeloma. Clin lymphoma myeloma 8: 237-240, 2008.
22. Palumbo A, Bringhen S, Caravita T, Merla E, Capparella V, Callea V, Cangialosi C, Grasso M, Rossini F, Galli M, Catalano L, Zamagni E, Petrucci MT, De Stefano V, Ceccarelli M, Ambrosini MT, Avonto I, Falco P, Ciccone G, Liberati AM, Musto P and Boccadoro M; Italian Multiple Myeloma Network, GIMEMA: Oral melphalan and prednisone chemotherapy plus thalidomide compared with melphalan and prednisone alone in elderly patients with multiple myeloma: Randomised controlled trial. Lancet 367: 825-831, 2006.
23. Facon T, Mary JY, Hulin C, Benboubker L, Attal M, Pegourie B, Renaud M, Harousseau JL, Guillerm G, Chaleteix C, Dib M, Voillat L, Maisonneuve H, Troncy J, Dorvaux V, Monconduit M, Martin C, Casassus P, Jaubert J, Jardel H, Doyen C, Kolb B, Anglaret B, Grosbois B, Yakoub-Agha I, Mathiot C and Avet-Loiseau H; Intergroupe Francophone du Myélome: Melphalan and prednisone plus thalidomide versus melphalan and prednisone alone or reduced-intensity autologous stem cell transplantation in elderly patients with multiple myeloma (IFM 99-06): A randomised trial. Lancet 370: 1209-1218, 2007.
24. Matsumoto M, Yamada T, Yoshinaga SK, Boone T, Horan T, Fujita S, Li Y and Mitani T: Essential role of NF-kappa B-inducing kinase in T-cell activation through the TCR/CD3 pathway. J Immunol 169: 1151-1158, 2002.
25. Blanco B, Pérez-Simón JA, Sánchez-Abarca LI, Carvajal-Vergara X, Mateos J, Vidriales B, López-Holgado N, Maiso P, Alberca M, Villarón E, Schenkein D, Pandiella A and San Miguel J: Bortezomib induces selective depletion of alloreactive T-lymphocytes and decreases the production of Th1 cytokines. Blood 107: 3575-3583, 2006.
26. Weller S, Blum MR, Doucette M, Burnette T, Cederberg DM, de Miranda P and Smiley ML: Pharmacokinetics of the acyclovir pro-drug valaciclovir after escalating single- and multiple-dose administration to normal volunteers. Clin Pharmcol Ther 54: 595-605, 1993.
27. Brantley JS, Hicks L, Sra K and Tyring SK: Valacyclovir for the treatment of genital herpes. Expert Rev Anti Infect Ther 4: 367-376, 2006.